68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy

Journal of Nuclear Medicine

Volumn 50, Issue 9, 2009, Pages 1427-1434

  Gabriel, Michael ^a   Oberauer, Andreas ^a   Dobrozemsky, Georg ^a   Decristoforo, Clemens ^a   Putzer, Daniel ^a   Kendler, Dorota ^a   Uprimny, Christian ^a   Kovacs, Peter ^a   Bale, Reto ^a   Virgolini, Irene J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Gallium 68; Neuroendocrine; Neuroendocrine tumors; Peptide related radionuclide therapy; PET; Radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID N,N',N'',N''' TETRAACETIC ACID DEXTRO PHENYLALANINE TYROSINE OCTREOTIDE GA 68; GALLIUM 68; OCTREOTIDE; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; 68GA DOTATATE; 68GA-DOTATATE; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER DISEASE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR REGRESSION; COMPARATIVE STUDY; EVALUATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 69449088669     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.053421     Document Type: Article

References (25)

1. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723-734. (Pubitemid 47123757)
2. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
3. 177Lu-DOTA0,Tyr3] octreotate. J Clin Oncol. 2004;22:2724-2729.
4. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands: an epidemiological study with 2,391 patients. Ann Oncol. 2001;12:1295-1300.
5. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
6. Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999;86:1621-1627. (Pubitemid 29489800)
7. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689-2696. (Pubitemid 46606312)
8. Gabriel M, Decristoforo C, Kendler C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518. (Pubitemid 47571404)
9. Gabriel M, Andergassen U, Putzer D, et al. Innsbruck experience with targeted radionuclide therapy using different radiolabeled somatostatin analogs [abstract]. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S220.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
11. Oberg K, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastro-enteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(suppl 2):ii104-ii105.
12. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460-466.
13. 68Ga-labelled peptides. Nucl Med Commun. 2007;28:870-875.
14. Krenning EP, Valkema R, Kwekkeboom DJ, et al. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. J Nucl Med. 2005;46(suppl):76S-82S. (Pubitemid 47619022)
15. 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140:968-976.
16. 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006;26:703-707.
17. 90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1038-1046.
18. 90Y-DOTATOC. J Nucl Med. 2005;46:1310-1316.
19. 90Y-DOTATOC. J Nucl Med. 2002;43:610-616.
20. 3-octreotide SPECT and diagnostic CT using an immobilization device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging. 2005;32:1440-1451.
21. Pfannenberg AC, Aschoff P, Brechtel K, et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol. 2007;80:437-445. (Pubitemid 47322230)
22. Belhocine T, Foidart J, Rigo P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727-734. (Pubitemid 34837002)
23. 18F-FDG. Cancer. 2008;112:2447-2455.
24. Lebtahi R, Cadiot G, Delahaye N, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med. 1999;40:1602-1608. (Pubitemid 29471148)
25. 90Y-DOTA-TOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115-1122.